MedTrace Logo

A Study of MHB036C for Advanced Solid Tumor

NCT06373406 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-11-19

No results posted yet for this study

Summary

Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of MHB036C in advanced malignant tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

MHB036C

An antibody-drug conjugate therapy

Sponsors & Collaborators

  • Minghui Pharmaceutical (Hangzhou) Ltd

    lead INDUSTRY

Principal Investigators

  • Shun Lu · Shanghai Chest Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-26
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06373406 on ClinicalTrials.gov